Antibodies to Watch in 2023
Thursday January 12, 2023, 11am ET / 4pm CET
Speakers: Drs. Janice Reichert, Silvia Crescioli, Alicia Chenoweth & Jyothsna Visweswaraiah
“Antibodies to Watch in 2023” highlights key events in commercial monoclonal antibody therapeutics development that occurred in 2022 and forecasts events that might occur in 2023. In this presentation, we will discuss the antibody therapeutics granted first approvals in either the United States or European Union in 2022, which include 4 bispecific antibodies ((tebentafusp, faricimab, mosunetuzumab and teclistamab) and 1 ADC (mirvetuximab soravtansine). We will also discuss approvals for antibody therapeutics that were first granted in China or Japan in 2022, which include 2 bispecific antibodies (cadonilimab and ozoralizumab). Globally, at least 24 investigational antibody therapeutics are undergoing review by regulatory agencies. Our data show that, with antibodies for COVID-19 excluded, the late-stage commercial clinical pipeline grew by ~20% in the past year to include nearly 140 investigational antibody therapeutics that were designed using a wide variety of formats and engineering techniques. Of those in late-stage development, marketing application submissions for at least 23 may occur by the end of 2023, of which 5 are bispecific (odronextamab, erfonrilimab, linvoseltamab, zanidatamab, and talquetamab) and 2 are ADCs (datopotamab deruxtecan, and tusamitamab ravtansine).
Registration is open!
Comprehensive Analysis and Engineering of Human Antibody Immunity
Thursday January 26, 2023, 11am ET / 4pm CET
Speaker: Brandon DeKosky, Assistant Professor in the Department of Chemical Engineering at MIT and a Core Member of the Ragon Institute of MGH, Harvard, and MIT
Mapping the molecular features of antibody immune responses has remained a challenge for many years, partly due to the high genetic diversity that is encoded by millions of single immune cells. This presentation summarizes the past several years of progress we have made in large-scale sequencing and functional screening of antibody immune libraries. We will also share unpublished data and recent advances for antibody discovery in complex cell populations and against difficult disease targets.
Registration is open!
Note: The webinar platform and registration process is managed by Community Brands.
Their privacy policy is here.
Our selection of On Demand webinars can be viewed here.
Recordings of our Symposia on topics such as
1) Biopharmaceutical Informatics,
2) Harnessing Cytokines for Cancer Immunotherapy,
3) Emerging Immunotherapeutics for Ovarian Cancer Symposium, and
4) Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells can be viewed on our YouTube channel.
